Trial · NCT02181790
Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles
NCT02181790, Phase 4, Terminated, Icahn School of Medicine at Mount Sinai; results first posted 2017-05-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles. Trials, record NCT02181790. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02181790
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles
- NCT number
- NCT02181790
- Status
- Terminated
- Phases
- Phase 4
- Enrollment
- 2 participants, actual
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Conditions
- Psoriasis, Skin or Nails
- Interventions
- Excimer laser, Acitretin
- First posted
- 2014-07-04
- Last updated
- 2021-03-10
- Results first posted
- 2017-05-02
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Psoriasis Area and Severity Index (PASI) | baseline and week 12 | The percentage of patients achieving a 75% reduction in the Psoriasis Area and Severity Index (PASI) from baseline after 16 treatments with the excimer laser in the first phase of the study. |
| Primary | Change in Dermatology Life Quality Index (DLQI) at Week 8 From Baseline | baseline and week 8 | reduction in DLQI from baseline after 16 treatments with the excimer laser in the first phase of the study |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Psoriasis Area and Severity Index (PASI) | baseline and week 12 | study terminated before study completion, no data collected | ||
| PRIMARY | Change in Dermatology Life Quality Index (DLQI) at Week 8 From Baseline | baseline and week 8 | study terminated before study completion, no data collected |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Excimer Laser (One Palm/Sole) | 2 | |
| Overall Study | STARTED | Excimer Laser (Both Palms/Soles) | 0 | |
| Overall Study | COMPLETED | Excimer Laser (One Palm/Sole) | 0 | |
| Overall Study | COMPLETED | Excimer Laser (Both Palms/Soles) | 0 | |
| Overall Study | NOT COMPLETED | Excimer Laser (One Palm/Sole) | 2 | |
| Overall Study | NOT COMPLETED | Excimer Laser (Both Palms/Soles) | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | First Group | 0 | 2 |
| Total, all-cause mortality | Second Group | 0 | 0 |
| Total, other adverse events | First Group | 0 | 2 |
| Total, other adverse events | Second Group | 0 | 0 |
| Total, serious adverse events | First Group | 0 | 2 |
| Total, serious adverse events | Second Group | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02181790
GET https://conductscience.org/api/trials/v1/NCT02181790/registered